ALMIRALL S.A. – Consensus Indicates Potential -3.3% Downside

DirectorsTalk Interviews

ALMIRALL S.A. with ticker code (ALM.MC) have now 9 analysts covering the stock pointing to an overall recommendation of ‘hold’. The target price ranges between €12.30 and €9.6 with the average target price sitting at €10.83. Given that the previous closing stock price was at €11.20 this is indicating there is a potential downside of -3.3%. There is a 50 day moving average of €11.35 while the 200 day moving average is €10.31. The market cap for the company is €2b. Visit the company website at:

Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, cutaneous T-cell lymphoma, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications; and for central nervous system, cardiovascular, and gastrointestinal diseases. Its products include Actikerall, Solaraze, Cordran Tape, Skilarence, Ilumetri, Seysara, Almax, Crestor, Provisacor, Sativex, Ebastel, Aczone, Tazorac, Azelex, and Veltin. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases; collaborative research and license agreement with X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases; research collaboration with Iktos in the area of artificial intelligence for new drug design; multi-target research collaboration with the University of Dundee to develop novel targeted protein degraders medicines; and collaboration with Popit to provide a novel support solution for patients with psoriasis. It also has a strategic partnership with Tyris Therapeutics to develop gene therapies for the treatment of rare genetic dermatology diseases; and Happify Health to develop evidence-supported digital therapeutics solutions for psoriasis patients. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:


      AIM All Share Index